Detailed Narrative
Q4 & FY26 Financial Performance Overview
Excel Industries reported a strong recovery in Q4 FY26, with standalone revenues reaching INR281 crores, a 13% year-on-year increase from INR248 crores in Q4 FY25. Adjusted EBITDA for the quarter also grew by 13% to INR22 crores, maintaining an 8% margin. For the full financial year FY26, net operating revenues stood at INR1,094 crores, reflecting an 11.8% growth compared to INR978 crores in FY25. The full-year Adjusted EBITDA was INR112 crores with a margin of 10.1%, and PAT reached INR73 crores with a 6.7% margin.
Strategic Business Updates and Capacity Expansion
The company successfully operationalized a 2,530 tons per annum capacity addition in its biocides range in the second half of FY26. Progress on a contract manufacturing agreement with a multinational company, announced in May 2024, is on track, with validation batches dispatched and the dedicated capacity expected to come on stream by July 2026. Excel also launched a new corporate R&D center at Rabale, Navi Mumbai, reinforcing its commitment to innovation and long-term value creation across its business verticals.
Raw Material Dynamics and Market Conditions
The first half of FY26 was challenging for the Indian agrochemical sector due to an extended monsoon, which impacted sowing, harvesting, and led to channel inventory build-up. While the company has largely been able to pass on raw material price increases in April and May, geopolitical developments are causing challenges in raw material availability and prices for Q1 FY27. Management noted that pricing strategy is dynamic and agile due to competition from China, and they are going for shorter pricing windows for products.
Long-Term Strategy and Growth Drivers
Excel Industries is focused on growth in Performance Solutions, contract manufacturing, and YP derivatives, with plans to launch one more biocide product in the second half of FY26. The company aims to increase its export share, particularly in the EU and US markets, leveraging opportunities like the EU FTA. While not pursuing broad chemistry diversification, the strategy is to deepen expertise and augment opportunities within phosphorus chemistry through R&D and technical capabilities.
Capital Allocation and Shareholder Returns
The company maintains a strong balance sheet with zero long-term debt and a net cash positive position, providing a cushion for operational challenges and strategic investments. Management indicated a capex plan of INR200-300 crores over the next three years, targeting a fixed asset turnover of 1 to 1.5 times and an ROI of 15% to 20%. The Board declared a final dividend of INR13.75 per equity share, representing 275% of the INR5 face value, demonstrating commitment to rewarding shareholders.